Project Grant SB1HL182474
Award Date 9/10/25
Completion Date 8/31/27
Dollars Obligated $322K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21230, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $269,922 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Steth X Microsystems Inc. to develop a smart, wearable contact microphone patch for extended and remote monitoring of lung functions. The goal is to create a low-profile, battery-powered wireless device capable of accurately detecting and quantifying adventitious lung sounds as well as breathing abnormalities in patients with respiratory...
- This federal Project Grant award from the National Heart Lung and Blood Institute under CFDA Program 93.837 - Cardiovascular Diseases Research provides $306,872 to Airalux Medical, Inc. to develop a digital incentive spirometry device. The goal is to improve patient adherence and clinical workflows for preventing post-surgical lung complications, which occur in 1 in 20 patients undergoing an overnight hospital stay. The device uses sensors and software to automatically track patient usage and...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, awarded a $310,948 Project Grant to Minnesota Healthsolutions Corporation, a for-profit woman-owned small business, on September 15, 2023. The grant funds the development of an adaptable platform to support patients with behavior change interventions aimed at improving adherence to treatment and prevention for multiple chronic diseases. The platform will utilize remote...
- This Project Grant award of $807,067.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will support a study to pioneer the quantitative documentation of human respiratory kinematic profiles. The study aims to address a critical gap in contemporary physiological monitoring - the inability to quantify labored breathing, which contains vital prognostic information not captured by conventional monitoring. Building on a recent innovation called ARK...
- The National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research grant program (CFDA 93.837), awarded $793,956 to Resuscitation Innovations LLC, doing business as Advancedcpr Solutions LLC, for the project "HEAD UP CPR AND AORTIC OCCLUSION TO IMPROVE SURVIVAL AFTER REFRACTORY CARDIAC ARREST". This project grant, awarded on January 1, 2025 with a planned completion date of January 23, 2026, aims to develop and evaluate new treatments to improve...
- The National Heart, Lung, and Blood Institute (NHLBI), via the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $564,445 Project Grant to the University of Texas Health Science Center at Houston (UTHealth) to fund research on "Targeting Hypoxia-Inducible Factors (HIFs) for Heart and Lung Disease." The 6-year grant, starting on March 1, 2025 and ending on December 31, 2031, supports three complementary research projects focused on investigating the upstream regulation...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $400,000 Project Grant to Electronic Biosciences, Inc. on Sep 20, 2024. The grant supports the development of an innovative analytical testing device to quantitatively characterize lipoprotein particles in blood. This technology will enable rapid, precise, and cost-effective measurement of lipoprotein size, concentration, and other physical properties, which are...
- The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $294,023 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Heartlung Corporation to develop the AUTOCHAMBER AI tool. AUTOCHAMBER is designed to opportunistically screen existing chest CT scans for early detection of enlarged cardiac chambers and left ventricular hypertrophy, which can indicate risk of atrial fibrillation, stroke, and heart failure. The project...
- The National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research program (CFDA 93.837), has awarded a $1,535,439 Cooperative Agreement to The Ohio State University (OSU) for the "WIN Ratio Analysis to Determine a Strategy of Non-Invasive Support for Respiratory Failure in the Emergency Department (WINDSURFER)" project. The project aims to determine the best initial non-invasive respiratory support strategy for treating acute hypoxemic respiratory...
- This federal Project Grant award of $710,302 from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program aims to investigate the origin and characterize the functional state of the lung interstitial neutrophil (LIN) subset. The project seeks to advance the understanding of the function, fate, pathophysiological role, and origin of LINs, and explore their therapeutic potential. The research will be conducted by Brigham & Women's...